Medicines List

Description

Pisizif SR contains indapamide – a non-thiazide sulphonamide diuretic. Most diuretics increase the amount of urine produced by the kidneys. Indapamide increases the urinary secretion of sodium and chloride ions and, to a lesser extent, the excretion of potassium and magnesium, thus increasing urine output and having an antihypertensive effect.

Indications

Pisizif SR is indicated for the treatment of essential hypertension.

Subject to medical prescription.

Concentration and pharmaceutical form: 1,5 mg prolonged release tablets

Description

Anastrozole is a powerful and highly selective non-steroidal aromatase inhibitor used to treat breast cancer after surgery and for metastases in both pre and post-menopausal women.

Indications

–  Treatment of advanced breast cancer in postmenopausal women. Efficacy has not been demonstrated in oestrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen.

–  Adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer.

–  Adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

Subject to medical prescription

Pharmaceutical form: 1 mg x 28 film-coated tablets

NHIF code: LF156 ICD: C50

Description

Peximyr contains the active substance pramipexole and belongs to a group of medicines known as dopamine agonists, which stimulate dopamine receptors in the brain. Stimulation of the dopamine receptors triggers nerve impulses in the brain that help to control body movements.

Indications

Peximyr is used to:
– treat the symptoms of primary Parkinson’s disease in adults. It can be used alone or in combination with levodopa (another medicine for Parkinson’s disease);
– treat the symptoms of moderate to severe primary Restless Legs Syndrome in adults.

Subject to medical prescription.

Concentration and pharmaceutical form: 0,18 mg; 0,7 mg tablets

Description

PlaquEx contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products. By preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming.

Indications

Secondary prevention of atherothrombotic events
Clopidogrel is indicated in:
– adult patients suffering from myocardial infarction (from a few days to 35 days), ischaemic stroke (from the 7^th day to the 6^th month) or established peripheral arterial disease;
– adult patients suffering from acute coronary syndrome:
– non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
– ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.

Prevention of atherothrombotic and thromboembolic events in atrial fibrillation
In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.

Subject to medical prescription.

Concentration and pharmaceutical form: 75 mg film-coated tablets